Cited by 34Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease

Open access
Higuchi, Makoto·2009·Current Alzheimer Research

Abstract

OBJECTIVES: Microglial overactivation, which is secondary to abnormalities of amyloid-beta peptide (Abeta) and tau proteins in the pathogenic cascade leading to onset of Alzheimer's disease (AD), accelerates tau pathology, according to our recent observations using mouse models of tauopathies, and this positive feedback results in formation of a vicious cycle between upstream and downstream processes, potentially hampering effective suppression of the entire cascade by anti-amyloid treatments. This motivates our present work aimed at dual monitoring of amyloidosis and microgliosis in living animal models of AD, toward therapeutic regulation of these two processes capable of halting the self-perpetuating cycle. METHODS: Transgenic mice expressing mutant amyloid precursor protein (APP23 mice) was examined by high-resolution positron emission tomography (PET) after administration of amyloid probe, Pittsburg Compound B (PIB) synthesized with high specific radioactivity (SA). Microglial activation in these mice was also imaged by PET and specific tracer, [(18)F]fluoroethyl-DAA1106. RESULTS: Progressive amyloidosis in APP23 mice was visualized by PET and high-SA PIB. In vitro assays revealed preferential binding of PIB to N-terminally modified Abeta, Abeta(N3pE). As levels of this Abeta subspecies in model mice are lower than those in AD patients, our findings plausibly explain advantages of high-SA tracers in sensitive detection of mouse amyloid. Near-simultaneous monitoring of amyloid removal and microgliosis in APP23 mice following injection of anti-Abeta antibody demonstrated positive correlation between levels of initially existing amyloid and antibody-induced microglial activation, suggesting the possibility of microglial overactivation in immunotherapy for subjects with abundant amyloid. CONCLUSIONS: The present animal imaging system would substantially facilitate establishment of a safe and effective therapeutic strategy targeting multiple key processes in the AD pathogenesis.

Integrity signals

Registry

Crossref · 10.2174/156720509787602906

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PiB may bind preferentially to amyloid plaques containing pE3Aβ, and if other amyloid PET ligands do the same, this preferential binding might overestimate the extent of amyloid clearance.

    “There are data that show that the amyloid PET ligand PiB may bind preferentially to amyloid plaques containing the pE3Aβ species 93,94 and although it is not known whether this is the case for other amyloid PET ligands, such preferential binding might over-estimate the extent of amyloid clearance.”

Cited by

Sorted by citations

Authors
Higuchi, M.
Affiliations
National Institute of Radiological Sciences (JP)
Corresponding author
Higuchi, Makoto
Venue
Current Alzheimer Research
Published
2009-04-01
Volume
6
Issue
2
Pages
137-143
ISSN
1567-2050 (ISSN-L)
OpenAlex
W1978902831
Cited by
34
References
0
Citations by year
2023: 1 · 2022: 1 · 2021: 1 · 2018: 1 · 2016: 2 · 2015: 3 · 2014: 4 · 2013: 5 · 2012: 5
FWCI
3.55
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Current Alzheimer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
Funders
  • University of Pennsylvania
  • Novartis Institutes for BioMedical Research
  • RIKEN Brain Science Institute
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, amyloid-beta, microglial activation, amyloidosis, APP23 mice, Pittsburgh compound B, anti-amyloid immunotherapy, positron emission tomography, tau pathology
MeSH terms
Acetamides, Alzheimer Disease, Aniline Compounds, Animals, Autoradiography, Brain, Brain Mapping, Disease Models, Animal, Humans, Isotopes, Mice, Transgenic, Mutation, Phenyl Ethers, Protein Binding, Thiazoles, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Microglia, Positron-Emission Tomography, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review